GSK Pakistan profit soars 74% to Rs6bn in 9MFY25

October 24, 2025 (MLN): GlaxoSmithKline Pakistan Limited (PSX: GLAXO) has reported a consolidated profit after tax of Rs6.23 billion for the nine months ended September 30, 2025, showing a robust increase of 74.03% compared to Rs3.58bn in the same period last year.

Total revenue from contracts with customers grew modestly by 2.03% to Rs44.49bn during 9MFY25, compared to Rs43.60bn in the corresponding period of FY24.

Gross profit witnessed exceptional growth of 66.81% to Rs15.92bn, as cost of sales declined significantly by 16.11% to Rs28.57bn, demonstrating outstanding operational efficiency and superior cost management capabilities.

Operating profit surged 79.32% to Rs10.48bn, driven by strong margin expansion despite higher operating expenses. Selling, marketing and distribution expenses increased 20.34% to Rs3.89bn, while administrative expenses rose 11.15% to Rs1.55bn.

Other operating expenses increased substantially by 83.97% to Rs902.06m. However, other income declined 36.33% to Rs902.23m from Rs1.42bn in the previous year.

Finance charges decreased 29.06% to Rs171.49m, compared to Rs241.73m in 9MFY24, providing relief amid the evolving interest rate environment and reflecting improved working capital management.

Profit before levies and income tax surged 84.00% to Rs10.31bn, up from Rs5.60bn in the same period last year.

Levies in the form of minimum tax increased modestly by 8.63% to Rs47.06m. Profit before income tax stood at Rs10.26bn, representing an impressive 84.59% year-on-year growth.

Total income tax expense increased significantly by 103.71% to Rs4.03bn, showing higher profitability and the company's tax obligations on improved earnings.

Despite higher taxation, profit after tax reached Rs6.23bn, with earnings per share (EPS) recorded at Rs19.57, up substantially from Rs11.25 in the same period last year, representing a 73.96% year-on-year growth.

Total comprehensive income for the period matched profit after taxation at Rs6.23bn, compared to Rs3.58bn in 9MFY24.

The strong performance reflects GlaxoSmithKline Pakistan's exceptional cost optimization, improved operational efficiency, and robust profit margins during the nine-month period, positioning the pharmaceutical giant as a standout performer in Pakistan's healthcare sector.

Copyright Mettis Link News